Weakened in R&D investments of listed pharmaceutical companies
It is known that listed pharmaceutical companieshave taken a step backon investments in research and development (R&D).
According to the YakupDotCom’s (www.yakup.com) analysis result of the 55 listed pharmaceutical companies’quarterly sales reports on the third quarter in 2014, R&D investments o...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
